You are here

Recent Pfizer Press Releases

1/5/17 8:30am EST
Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab)

Marks Pfizer’s third proposed biosimilar pipeline molecule2 to report positive top-line data results within the past four months

Pfizer Inc. (NYSE:PFE) today announced that the comparative, confirmatory REFLECTIONS B538-02 study met its primary objective by demonstrating equivalent efficacy as measured by the American College of Rheumatology 20 (ACR20) response rate at Week 12. This trial is evaluating the efficacy, safety, and immunogenicity of PF-06410293 compared to Humira® (adalimumab), each taken in combination with methotrexate, in patients with moderate to severe rheumatoid arthritis. PF-06410293 is being developed as a potential biosimilar to Humira.

more...
1/3/17 11:00am EST
Pfizer Invites Public To View And Listen To Webcast Of January 31 Conference Call With Analysts

Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 31, 2017. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2016 Performance Report, to be issued that morning.

more...
1/3/17 10:00am EST
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Group President, Pfizer Innovative Health, Frank D’Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, and Mikael Dolsten, President, Worldwide Research and Development, and at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 10:30 a.m. Pacific Standard Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “35th Annual J.P.

more...